Key Points
-
Traditionally, genetic disorders have been classified as monogenic (involving one gene) or complex (involving many genes and their interaction with each other and the environment).
-
The identification of numerous disease genes has revealed that the pattern of transmission of certain genetic diseases deviates from the monogenic model.
-
Oligogenic disorders manifest a spectrum of complexity ranging from the phenotypic modification of a single allele by an allele at another locus, to complex gene and protein relationships.
-
Traditional tools for investigating complex relationships between genes can be successful in establishing the oligogenic basis of a genetic disorder and for modelling oligogenic traits using Mendelian principles.
-
The establishment of oligogenic behaviour and the expansion of models to explain the inheritance of disease alleles can catalyse the discovery of new disease genes through functional approaches.
-
In the absence of functional assays or an animal model, oligogenic mutations are often subtle and more difficult to recognize.
-
The molecular basis of oligogenicity requires a direct or indirect interaction of mutated proteins. These interactions might be due to the presence of multi-protein complexes, pleiotropic signalling pathways, complementary pathways or overlapping networks of protein function.
Abstract
Methodological and conceptual advances in human genetics have led to the identification of an impressive number of human disease genes. This wealth of information has also revealed that the traditional distinction between Mendelian and complex disorders might sometimes be blurred. Genetic and mutational data on an increasing number of disorders have illustrated how phenotypic effects can result from the combined action of alleles in many genes. In this review, we discuss how an improved understanding of the genetic basis of multilocus inheritance is catalysing the transition from a segmented view of human genetic disease to a conceptual continuum between Mendelian and complex traits.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Scriver, C. R. & Waters, P. J. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet. 15, 267–272 (1999).
Dipple, K. M. & McCabe, E. R. B. Phenotypes of patients with 'simple' Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am. J. Hum. Genet. 66, 1729–1735 (2000).Illustrates the increasing levels of complexity that are seen in 'simple' Mendelian disorders and presents thresholds models to correlate mutations with phenotypes.
Dipple, K. M. & McCabe, E. R. B. Modifier genes convert 'simple' Mendelian disorders to complex traits. Mol. Genet. Metab. 71, 43–50 (2000).
Weiss, K. M. Is there a paradigm shift in genetics? Lessons from the study of human diseases. Mol. Phylogenet. Evol. 5, 259–265 (1996).
Jervis, G. A. Phenylpyruvic oligophrenia deficiency of phenylalanine-oxidizing system. Proc. Soc. Exp. Biol. Med. 82, 514–515 (1953).
Guthrie, R. & Susi, A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32, 338–343 (1963).
Guthrie, R. The introduction of newborn screening for phenylketonuria: a personal history. Eur. J. Pediat. 155, 4–5 (1996).
Scriver, C. R. Whatever happened to PKU? Clin. Biochem. 28, 137–144 (1995). Comprehensive revision of phenylketonuria and its history, as well as a useful discussion of the complex genetics of this disorder.
Woo, S. L. C., Lidsky, A. S., Guttler, F., Chandra, D. & Robson, K. J. H. Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria. Nature 306, 151–155 (1983).
Blau, N., Thony, B., Heizmann, C. W. & Dhondt, J.-L. Tetrahydrobiopterin deficiency: from phenotype to genotype. Pteridines 4, 1–10 (1993).
Enns, G. M. et al. Molecular correlations in phenylketonuria: mutation patterns and corresponding biochemical and clinical phenotypes in a heterogeneous California population. Pedriatr. Res. 46, 594–602 (1999).
Tsui, L. C. et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 230, 1054–1057 (1985).
Riordan, J. R. et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073 (1989).
Acton, J. D. & Wilmott, R. W. Phenotype of CF and the effects of possible modifier genes. Pediatr. Respir. Rev. 2, 332–339 (2001).
Drumm, M. L. Modifier genes and variation in cystic fibrosis. Resp. Res. 2, 125–128 (2001).
Mickle, J. E. & Cutting, G. R. Genotype–phenotype relationships in cystic fibrosis. Med. Clin. N. Am. 84, 597–607 (2000).
Nadeau, J. H. Modifier genes in mice and humans. Nature Rev. Genet. 2, 165–174 (2001).An elegant and comprehensive discussion of modifier genes and the lessons that can be learned from studying mouse models of human disease.
Zielenski, J. Genotype and phenotype in cystic fibrosis. Respiration 67, 117–133 (2000).
Zielenski, J. et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nature Genet. 22, 128–129 (1999).
Rozmahel, R. et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nature Genet. 12, 280–287 (1996).
Arkwright, P. D. et al. TGF-β(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 55, 459–462 (2000).
Hull, J. & Thomson, A. H. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 53, 1018–1021 (1998).
Aron, Y. et al. HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype. Am. J. Respir. Crit. Care Med. 159, 1464–1468 (1999).
Garred, P. et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J. Clin. Invest. 104, 431–437 (1999).
Grasemann, H. et al. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am. J. Respir. Crit. Care Med. 162, 2172–2176 (2000).
Parmley, R. R. & Gendler, S. J. Cystic fibrosis mice lacking Muc1 have reduced amounts of intestinal mucus. J. Clin. Invest. 102, 1798–1806 (1998).
Wang, X. et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 284, 1814–1819 (2000).
Groman, J. D., Meyer, M. E., Wilmott, R. W., Zeitlin, P. L. & Cutting, G. R. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N. Engl. J. Med. 347, 401–407 (2002).
Polanyi, M. Life's irreducible structure. Live mechanisms and information in DNA are boundary conditions with a sequence of boundaries above them. Science 160, 53–91 (1968).
Strohman, R. Maneuvering in the complex path from genotype to phenotype. Science 296, 701–703 (2002).
Sawa, A. & Snyder, S. H. Schizophrenia: diverse approaches to a complex disease. Science 296, 692–695 (2002). An in-depth review of approaches to studying the pathogenesis of schizophrenia.
Hand, C. K. & Rouleau, G. A. Familial amyotrophic lateral scloerosis. Muscle Nerve 25, 135–159 (2002).
Giess, R. et al. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am. J. Hum. Genet. 70, 1277–1286 (2002).Description of how, in an ALS patient, CNTF modulates the severity of a SOD1 mutation.
Takahashi, R. et al. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nature Genet. 7, 79–84 (1994).
Su, L. K. et al. A germ line mutation of the murine homolog of the APC gene causes multiple intestinal neoplasia. Science 256, 668–670 (1992).
Moser, A. R., Dove, W. F., Roth, K. A. & Gordon, J. I. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J. Cell Biol. 116, 1517–1526 (1992).
Moser, A. R., Pitot, H. C. & Dove, W. F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322–324 (1990).
Dietrich, W. F. et al. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75, 631–639 (1993).
Coleman, D. L. & Eicher, E. M. Fat (fat) and Tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse. J. Hered. 81, 424–427 (1990).
Noben-Trauth, K., Naggert, J. K., North, M. A. & Nishina, P. M. A candidate gene for the mouse mutation tubby. Nature 380, 534–538 (1996).
Kleyn, P. W. et al. Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Cell 85, 281–290 (1996).
Ikeda, A. et al. Genetic modification of hearing in tubby mice: evidence for the existence of a major gene (Moth1) which protects tubby mice from hearing loss. Hum. Mol. Genet. 8, 1761–1767 (1999).
Ikeda, A. et al. Microtubule-associated protein 1A is a modifier of tubby hearing (moth1). Nature Genet. 30, 401–405 (2002). Cloning of the genetic modifier of tubby and the demonstration, through the use of transgenic animals, that sequence polymorphisms in Map1a are responsible for protection against the hearing defect of tubby mutant mice.
Kajiwara, K., Berson, E. L. & Dryja, T. P. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science 264, 1604–1608 (1994). Shows that heterozygous mutations in two distinct genes are necessary and sufficient to cause RP in some patients. Probably the first example of digenic mutations in humans.
Rivolta, C., Sharon, D., DeAngelis, M. M. & Dryja, T. P. Retinitis pigmentosa and allied diseases: numerous diseases, genes, and inheritance patterns. Hum. Mol. Genet. 11, 1219–1227 (2002).
Katsanis, N. et al. Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet–Biedl syndrome. Nature Genet. 26, 67–70 (2000).
Slavotinek, A. M. et al. Mutations in MKKS cause Bardet–Biedl syndrome. Nature Genet. 26, 15–16 (2000).
Beales, P. L. et al. Genetic and mutational analyses of a large multiethnic Bardet–Biedl cohort reveal a minor involvement of BBS6 and delineate the critical intervals of other loci. Am. J. Hum. Genet. 68, 606–616 (2001).
Nishimura, D. Y. et al. Positional cloning of a novel gene on chromosome 16q causing Bardet–Biedl syndrome (BBS2). Hum. Mol. Genet. 10, 865–874 (2001).
Katsanis, N. et al. Triallelic inheritance in Bardet–Biedl syndrome, a Mendelian recessive disorder. Science 293, 2256–2259 (2001). First example of triallelic inheritance in humans, in a disease considered historically to be an autosomal-recessive trait.
Feingold, E. Regression-based quantitative-trait-Locus mapping in the 21st century. Am. J. Hum. Genet. 71, 217–222 (2002).
Moore, J. H. & Williams, S. M. New strategies for identifying gene-gene interactions in hypertension. Ann. Med. 34, 88–95 (2002).
McCallion, A. S. & Chakravarti, A. in Inborn Errors of Development (eds Epstein, C., Erickson, R. & Wynshaw-Boris, A. (Oxford Univ. Press, San Francisco, in the press).
Puffenberger, E. G. et al. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 79, 1257–1266 (1994).
Parisi, M. A. & Kapur, R. P. Genetics of Hirschsprung disease. Curr. Opin. Pediatr. 12, 610–617 (2000).
Amiel, J. & Lyonett, S. Hirschsprung disease, associated syndromes, and genetics: a review. J. Med. Genet. 38, 729–739 (2001).
Angrist, M. et al. A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10. Nature Genet. 3, 351–356 (1993).
Lyonnet, S. et al. A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10. Nature Genet. 4, 346–350 (1993).
Bolk-Gabriel, S. B. et al. Segregation at three loci explains familial and population risk in Hirschsprung disease. Nature Genet. 31, 89–93 (2002).
Bolk, S. et al. A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc. Natl Acad. Sci. USA 97, 268–273 (2000). References 59 and 60 establish statistical methods to analyse the documented oligogenicity of Hirschsprung disease.
Floeth, M. & Bruckner-Tuderman, L. Digenic junctional epidermolysis bullosa: mutations in COL17A1 and LAMB3 genes. Am. J. Hum. Genet. 65, 1530–1537 (1999).
Kestila, M. et al. Positionally cloned gene for a novel glomerular protein nephrin is mutated in congenital nephrotic syndrome. Mol. Cell 1, 575–582 (1998).
Patrakka, J. et al. Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. Kidney Int. 58, 972–980 (2000).
Boute, N. et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nature Genet. 24, 349–354 (2000).
Huber, T. B., Kottgen, M., Schilling, B., Walz, G. & Benzing, T. Interaction with podocin facilitates nephrin signaling. J. Biol. Chem. 276, 1543–1546 (2001).
Koziell, A. et al. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. Hum. Mol. Genet. 11, 379–388 (2002).
Mykytyn, K. et al. Identification of the gene that, when mutated, causes the human obesity syndrome BBS4. Nature Genet. 28, 188–191 (2001).
Katsanis, N. et al. BBS4 is a minor contributor to Bardet–Biedl syndrome and may also participate in triallelic inheritance. Am. J. Hum. Genet. 71, 22–29 (2002).
Stone, E. M. et al. Identification of a gene that causes primary open angle glaucoma. Science 275, 668–670 (1997).
Stoilov, I., Akarsu, A. N. & Sarfarazi, M. Identification of three different truncating mutations in cytochrome P450B1 (CYP1B1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 6, 641–647 (1997).
Fingert, J. H. et al. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum. Mol. Genet. 8, 899–905 (1999).
Bejjani, B. A. et al. Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus. Hum. Mol. Genet. 12, 367–374 (2000).
Bejjani, B. A. et al. Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. Am. J. Hum. Genet. 62, 325–333 (1998).
Vincent, A. L. et al. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. Am. J. Hum. Genet. 70, 448–460 (2002).
Hanna, I. H., Dawling, S., Roodi, N., Guengerich, F. P. & Parl, F. F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in hydrogen hydroxylation activity. Cancer Res. 60, 3440–3444 (2000).
Shimada, T., Watanabe, J., Inoue, K., Guengerich, F. P. & Gillam, E. M. Specificity of 17b-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P450B1 variants substituted at residues 48, 119 and 432. Xenobiotica 31, 163–176 (2001).
Shimada, T. et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20, 1607–1613 (1999).
Li, D. N., Seidel, A., Pritchard, M. P., Wolf, C. R. & Friedberg, T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 10, 343–353 (2000).
Goldberg, A. F. X. & Molday, R. S. Subunit composition of the peripherin/rds-rom-1 disk rim complex from rod photoreceptors: hydrodynamic evidence for a tetrameric quaternary structure. Biochemistry 35, 6144–6149 (1996).
Clark, G. et al. Rom-1 is required for rod photoreceptor viability and the regulation of disk morphogenesis. Nature Genet. 25, 67–73 (2000).
Travis, G. H., Brennan, M. B., Danielson, P. E., Kozak, C. A. & Sutcliffe, J. G. Identification of a photoreceptor-specific mRNA encoded by the gene responsible for retinal degeneration slow (rds). Nature 338, 70–73 (1989).
Loewen, C. J., Moritz, O. L. & Molday, R. S. Molecular characterization of the peripherin-2 and rom-1 mutants responsible for digenic retinitis pigmentosa. J. Biol. Chem. 276, 22388–22396 (2001).
Goldberg, A. F. & Molday, R. S. Defective subunit assembly underlies a digenic form of retinitis pigmentosa linked to mutations in peripherin/rds and rom-1. Proc. Natl Acad. Sci. USA 93, 13726–13730 (1996). References 82 and 83 illustrate the molecular basis of digenic inheritance involving ROM1 and RDS in human RP.
Schwartz, K. et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J. Clin. Invest. 108, 1621–1629 (2001).
Angrist, M., Bolk, S., Halushka, M., Lapchak, P. & Chakravarti, A. Germline mutations in glial cell-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nature Genet. 14, 341–344 (1996).
Durbec, P. et al. GDNF signaling through the Ret receptor tyrosine kinase. Nature 381, 789–793 (1996).
Treanor, J. J. et al. Characterization of a multicomponent receptor for GDNF. Nature 382, 80–83 (1996).
Li, L. et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nature Genet. 16, 243–251 (1997).
Oda, T. et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nature Genet. 16, 235–242 (1997).
McCright, B., Lozier, J. & Gridley, T. A mouse model for Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129, 1075–1082 (2002). Describes the molecular basis of phenotypic modification of the Jag1 mutation.
Yook, K. J., Proulx, S. R. & Jorgensen, E. M. Rules of nonallelic complementation at the synapse in Caenorhabditis elegans. Genetics 158, 209–220 (2001). A comprehensive analysis of non-allelic non-complementation and establishment of its parameters of action in the worm synapse.
Fuller, M. T. et al. Interacting genes identify interacting proteins involved in microtubule function in Drosophila. Cell Motil. Cytoskeleton 14, 128–135 (1989).
Stearns, T. & Botstein, D. Unlinked noncomplementation: isolation of new conditional-lethal mutations in each of the tubulin genes of Saccharomyces cerevisiae. Genetics 119, 249–260 (1988). A classic paper on the use of non-allelic non-complementation to study specific signalling pathways.
Westphal, I. V. et al. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency. Hum. Mol. Genet. 11, 599–604 (2002).
Gavin, A. C. et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415, 41–47 (2002).
Ho, Y. et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415, 180–183 (2002).
Scriver, C. R. Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics. J. Pediatr. 140, 502–506 (2002).
Allikmets, R. et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 277, 1805–1807 (1997).
Allikmets, R. et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nature Genet. 15, 236–246 (1997).
Sun, H., Smallwood, P. M. & Nathans, J. Biochemical defects in ABCR protein variants associated with human retinopathies. Nature Genet. 26, 242–246 (2000).
Shroyer, N. F., Lewis, R. A., Yatsenko, A. N., Wensel, T. G. & Lupski, J. R. Cosegregation and functional analysis of mutant ABCR (ABCA4) alleles in families that manifest both Stargardt disease and age-related macular degeneration. Hum. Mol. Genet. 10, 2671–2678 (2001). References 100 and 101 show the mutagenic potential of alleles for which pathogenicity had been disputed according to genetic criteria.
del Castillo, I. et al. A deletion involving the connexin 30 gene in nonsyndromic hearing impairment. N. Engl. J. Med. 346, 243–249 (2002).
Riazuddin, S. et al. Dominant modifier DFNM1 suppresses recessive deafness DFNB26. Nature Genet. 26, 431–434 (2000).
Adato, A. et al. Possible interaction between USH1B and USH3 gene products as implied by apparent digenic deafness inheritance. Am. J. Hum. Genet. 65, 261–265 (1999).
Balciuniene, J. et al. Evidence for digenic inheritance of nonsyndromic hereditary hearing loss in a Swedish family. Am. J. Hum. Genet. 63, 786–793 (1998).
Morell, R. et al. Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and autosomal recessive ocular albinism (AROA). Hum. Mol. Genet. 6, 659–664 (1997).
Richard, I. et al. Mutations in the proteolytic enzyme Calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81, 27–40 (1995).
Bolliger-Stucki, B., Lord, S. T. & Furlan, M. Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, α-R16C and γ-G165R. Blood 98, 351–357 (2001).
Goodyer, P. R., Clow, C., Reade, T. & Girardin, C. Prospective analysis and classification of patients with cystinuria identified in a newborn screening program. J. Pediatr. 122, 568–572 (1993).
Kerst, B. et al. Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy. Neuromuscul. Disord. 10, 572–577 (2000).
Redston, M. et al. The APCI1307K allele and breast cancer risk. Nature Genet. 20, 13–14 (1998).
Scharf, J. M. et al. Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nature Genet. 20, 83–86 (1998).
Phelan, C. M. et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet. 12, 309–311 (1996).
Knoblauch, H. et al. A cholesterol-lowering gene maps to chromosome 13q. Am. J. Hum. Genet. 66, 157–166 (2000).
Cazeneuve, C. et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am. J. Hum. Genet. 67, 1136–1143 (2000).
Bykhovskaya, Y. et al. Candidate locus for a nuclear modifier gene for maternally inherited deafness. Am. J. Hum. Genet. 66, 1905–1910 (2000).
Box, N. F. et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am. J. Hum. Genet. 69, 765–773 (2001).
Sertie, A. L., Sousa, A. V., Steman, S., Pavanello, R. C. & Passos-Bueno, M. R. Linkage analysis in a large Brazilian family with van der Woude syndrome suggests the existence of a susceptibility locus for cleft palate at 17p11. −2-11.−1. Am. J. Hum. Genet. 65, 433–440 (1999).
Gill, J. C., Endres-Brooks, J., Bauer, P. J., Marks, W. J. J. & Montgomery, R. R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69, 1691–1695 (1987).
Mohlke, K. L. et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 96, 111–120 (1999).
Wyss-Coray, T. et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nature Med. 7, 612–618 (2001).
Takaku, K. et al. Suppression of intestinal polyposis in ApcΔ716 knockout mice by an additional mutation in the cytosolic phospholipase A2 gene. J. Biol. Chem. 275, 34013–34016 (2000).
Oshima, M. et al. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803–809 (1996).
Vockley, J., Rinaldo, P., Bennett, M. J., Matern, D. & Vladutiu, G. D. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol. Genet. Metab. 71, 10–18 (2000).
Acknowledgements
We apologize to those researchers whose work we were unable to represent due to space constraints. We thank J. Groman and G. Cutting for sharing their unpublished data with us, and G. Cutting, S. Huston and J. Lupski for constructive discussions and critique of this manuscript. This work was supported by the National Eye Institute, the National Institutes of Health and by a grant from March of Dimes to N.K.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
LocusLink
OMIM
familial amyotrophic lateral sclerosis
Finnish congenital nephrotic syndrome
generalized atrophic benign epidermolysis bullosa
junctional epidermolysis bullosa
WormBase
FURTHER INFORMATION
Glossary
- PHENYLKETONURIA
-
An inborn error of metabolism that is caused by lack of the enzyme PAH that converts phenylalanine to tyrosine. If left untreated, it causes abnormally high phenylalanine levels and severe, progressive mental retardation, but can be prevented by neonatal screening and a low phenylalanine diet from an early age.
- TETRAHYDROBIOPTERIN
-
Phenylalanine hydroxylase (PAH) is an oxygenase that couples an electron from a tetrahydrobiopterin cofactor (BH4) and an oxygen atom to hydroxylate phenylalanine to form tyrosine. Consequently, any defects in BH4 biosynthesis impair PAH function.
- FAMILIAL ADENOMATOUS POLYPOSIS
-
(FAP). The development of numerous adomatous polyps in the colon that might progress to carcinomas.
- QUANTITATIVE TRAIT LOCUS
-
(QTL). A genetic locus or chromosomal region that contributes to variability in complex quantitative traits (such as height or body weight), as identified by statistical analysis. Quantitative traits are typically affected by several genes and by the environment.
- RETINITIS PIGMENTOSA
-
(RP). A group of both clinically and genetically heterogeneous hereditary retinal degeneration disorders that are caused by the death of both rod and cone photoreceptors, leading to a complete loss of vision.
- BARDET–BIEDL SYNDROME
-
(BBS). A rare and genetically heterogeneous disorder that is characterized primarily by obesity, retinal dystrophy, polydactyly, hypogenitalism, learning difficulties and renal malformations.
- HAPLOTYPE ANALYSIS
-
The study of the pattern of descent of a combination of alleles at different sites on a single chromosome (known as a haplotype). It is used for the identification of recombination events between markers and traits during linkage studies, thereby establishing the boundaries of the location of a phenotype-associated locus.
- CONSANGUINEOUS
-
Descended from a recent common ancestor.
- ENTERIC GANGLIA
-
Parasympathetic mass of nerve tissue (ganglia) in the colon.
- PENETRANCE
-
The proportion of affected individuals among the carriers of a particular genotype. If all individuals who have a disease genotype show the disease phenotype, then the disease is said to be “completely penetrant”.
- HERITABILITY
-
The proportion of the variation in a given characteristic or state that can be attributed to genetic factors.
- PARAMETRIC LINKAGE
-
Parametric analyses are statistical tests for linkage that use assumptions such as mode of transmission, allele frequencies and penetrance.
- NON-PARAMETRIC LINKAGE
-
Non-parametric approaches are statistical procedures that are not based on models, or assumptions pertaining to the distribution of the quantitative trait.
- LOD SCORE
-
(Base 10 'logarithm of the odds' or 'log-odds'). A method of hypothesis testing. The logarithm of the ratio between likelihoods under the null and alternative hypotheses.
- NEPHROTIC SYNDROME
-
Malfunction of the renal glomerular filtration barrier (a structure in the glomerulus that is responsible for protein filtration) that lead to the loss of plasma proteins.
- GLAUCOMA
-
The abnormally elevated pressure in the liquid that fills the anterior part of the eye (the aqueous humour).
- LINKAGE DISEQUILIBRIUM
-
The condition in which the frequency of a particular haplotype for two loci is significantly greater than that expected from the product of the observed allelic frequencies at each locus.
- GENETIC DRIFT
-
Random fluctuations in the allele and, less commonly, the phenotype frequencies, as genes are transmitted from one generation to the next.
- ALAGILLE SYNDROME
-
A dominantly inherited disorder that is characterized primarily by a scarcity of bile ducts in the liver. Other features include heart, eye, kidney and skeletal abnormalities, as well as defects in the central nervous system.
- HAPLOINSUFFICIENCY
-
A gene dosage effect that occurs when a diploid requires both functional copies of a gene for a wild-type phenotype. An organism that is heterozygous for a haploinsufficient locus does not have a wild-type phenotype.
Rights and permissions
About this article
Cite this article
Badano, J., Katsanis, N. Beyond Mendel: an evolving view of human genetic disease transmission. Nat Rev Genet 3, 779–789 (2002). https://doi.org/10.1038/nrg910
Issue Date:
DOI: https://doi.org/10.1038/nrg910
This article is cited by
-
Sequence variants in different genes underlying Bardet-Biedl syndrome in four consanguineous families
Molecular Biology Reports (2023)
-
Novel MYO15A variants are associated with hearing loss in the two Iranian pedigrees
BMC Medical Genetics (2020)
-
Joint utilization of genetic analysis and semi-cloning technology reveals a digenic etiology of Müllerian anomalies
Cell Research (2020)
-
Identification of Gene Mutations in Primary Pediatric Cardiomyopathy by Whole Exome Sequencing
Pediatric Cardiology (2020)
-
Using mechanistic models for the clinical interpretation of complex genomic variation
Scientific Reports (2019)